Pharmaceuticals News

The market for generic Ozempic is expanding, while Mounjaro continues to maintain its premium position in the pharmaceutical industry.

Sandoz aims to more than double its annual net sales by 2035, with biosimilars driving this growth, and plans to expand its biosimilar portfolio to 100 drugs by

India's pharma market is experiencing a significant shift with GLP-1 drugs gaining traction, as evidenced by Mounjaro's 502% sales surge to ₹1,256 crore. This g

RPG Life Sciences is expanding its API business after two acquisitions totaling ₹215 crore, increasing its manufacturing capacity fivefold and strengthening its

HRV Pharma is investing ₹150 crore in peptides and high-potency oncology APIs, marking a strategic shift in its business model. This investment moves the compan

Novartis India is set to acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for approximately ₹1,250 crore.

RPG Life Sciences has invested ₹215 crore in two acquisitions within five weeks, aiming for significant API expansion and plans to deploy an additional ₹500-700

Manual licence checks are now mandatory for pharmaceutical imports.

RPG Life Sciences is investing in building a drug-ingredients business, anticipating that the global shift away from reliance on China will benefit Indian manuf

RPG Life Sciences plans to invest Rs 500 crore over the next 12 months to enhance its manufacturing and API capabilities through strategic acquisitions. The com

Indian Immunologicals Limited stated that seized Abhayrab rabies vaccine vials were not manufactured by their company, despite a batch being labeled substandard

The US FDA has approved AstraZeneca's new breast cancer pill, Etcamah (camizestrant), for use in combination with other medicines for patients with a geneticall

Cipla has announced a partnership with China's Qilu Pharma to develop and commercialize a cancer biosimilar, reinforcing Cipla's focus on its oncology portfolio

Indian drugmakers are opposing a proposal that would make them solely responsible for medicine overpricing, arguing it unfairly exempts retail chemists, hospita

Despite severe supply chain disruptions from conflicts in West Asia, India's pharmaceutical exports grew 6.8% in Q1 FY27, according to Pharmexcil. The Pharmexci

The government plans to introduce new regulations requiring pharmaceutical companies to differentiate between biologics and synthetics to clarify ambiguity arou

Sun Pharma has agreed to supply its products to U.S. Medicaid programs at Most Favored Nation (MFN) pricing. The U.S. market is crucial for Sun Pharma, represen

Novo Nordisk's chief executive, Mike Doustdar, believes investors are underestimating the potential of the company's drugs, despite being a year into a corporat

Sun Pharma's recent pact in the US is anticipated to significantly influence India's pharmaceutical industry strategies.

Sun Pharma is strategically avoiding tariff impacts by agreeing to Most Favored Nation (MFN) pricing for US Medicaid, as the drugmaker expands its presence in i

Natco Pharma is exploring opportunities beyond generic drugs for future growth, as explained by CEO and Vice Chairman Rajeev Nannapaneni. He detailed how Indian

People are risking their health by obtaining Retatrutide, a weight-loss drug not yet approved by the FDA, through the gray market. This trend is driven by indiv

The Bombay High Court criticized the FDA for revoking a Pune drug firm's license, stating that the authority acted against the principles of natural justice.

The pharmaceutical industry is facing a significant challenge as over $500 billion in projected annual drug sales are at risk due to upcoming patent expirations